Clinical data revealed significantly reduced blood Occludin levels and faster functional recovery in NBO-treated AIS patients, suggesting blood Occludin as a potential biomarker for BBB integrity [119]. The gene discussed is OCLN; the disease is chronic recurrent multifocal osteomyelitis.